Animal models of Alport syndrome

Clifford E. Kashtan

Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA

Introduction

The last decade of the twentieth century was a very productive period for the study of Alport syndrome. Alport syndrome was shown to result from mutations in certain members of the type IV collagen family of proteins, the {alpha}3(IV), {alpha}4(IV), and {alpha}5(IV) chains. Several hundred different mutations in the COL4A5 gene, which encodes the {alpha}5(IV) chain, were described in patients with X-linked Alport syndrome [1]. A few dozen mutations were found in the COL4A3 and COL4A4 genes, which respectively encode the {alpha}3(IV) and {alpha}4(IV) chains, in patients with autosomal recessive Alport syndrome [2,3]. Autosomal dominant Alport syndrome, due to heterozygous mutations in COL4A3 or COL4A4, was established as an entity, and distinguished from Fechtner and Epstein syndromes, which arise from mutations in a non-collagen locus, MYH9 [47]. Investigators established that mutations in the {alpha}3(IV), {alpha}4(IV), or {alpha}5(IV) chain typically prevent expression of any of these proteins in glomerular basement membranes (GBM), because these chains must interact with each other in networks in order to be deposited in the GBM [8]. These chains are replaced in the GBM by {alpha}1(IV) and {alpha}2(IV) chains, which normally disappear, for the most part, from the GBM during the capillary loop stage of glomerular maturation [911]. Other extracellular matrix proteins, such as types V and VI collagen and the laminin {alpha}2 chain, are aberrantly expressed in the Alport GBM [9,12].

Despite these advances, key questions about Alport syndrome remain. Except perhaps for anterior lenticonus, for which it can be plausibly argued that reduced tensile strength of the lens capsule basement membrane prevents maintenance of normal lens shape, we have very little understanding of the pathogenesis of the extrarenal manifestations of Alport syndrome, in particular sensorineural deafness. We do not know how the Alport GBM loses its permselectivity, or why Alport kidneys fail. Of greatest importance, we do not have treatments of proven efficacy, and the nature of the disease—its relative rarity, its slow progression, and the strong influence of genotype on the severity of the Alport phenotype—will complicate efforts to conduct randomized clinical trials.

Animal models of genetic disorders provide opportunities for investigating both pathogenesis and treatment of disease. Fortunately, several excellent animal models of Alport syndrome have been developed (Table 1Go). Thus far, these models are limited to spontaneous Alport syndrome in dogs and transgenic models of Alport syndrome created in mice. This review provides a brief discussion of these models and their applicability to investigations of the pathogenesis and treatment of Alport syndrome, and of the biology of type IV collagen.


View this table:
[in this window]
[in a new window]
 
Table 1.  Animal models of Alport syndrome

 

X-linked Alport syndrome (XLAS)

About 80% of patients with Alport syndrome have the X-linked form of the disease. Two canine models of XLAS have been identified. The first of these was discovered in a strain of Samoyed dogs, and was found to result from a G to T substitution in exon 35 (of 51) of COL4A5, changing a glycine codon to a stop codon [13,14]. The second, found in a kindred of mixed-breed dogs from Navasota, Texas [15], arises from a 10-bp deletion in exon 9 of COL4A5 that creates a frame-shift and a stop codon in exon 10 (Cox M., Lees G., Kashtan C., Murphy K., submitted for publication). Affected animals in both models display ultrastructural changes in the GBM, and alterations in the GBM expression of collagen IV {alpha} chains, that are indistinguishable from those found in human Alport patients. Overt proteinuria appears in affected males during the first 6 months of life, and uraemia by 12–18 months. Affected males do not have clinically detectable deafness or ocular abnormalities.

At this time, there is no reported murine model of XLAS. A murine XLAS model would be valuable because XLAS is the predominant human form of the disease, and would facilitate investigation of the role of X-inactivation in determining outcome in female heterozygotes.

Autosomal recessive Alport syndrome (ARAS)

ARAS accounts for about 15% of patients with the disease. The existence of an inherited nephropathy in English cocker spaniels was known for many years, and in the 1980s this was shown to be a progressive glomerular disorder with autosomal recessive inheritance [16,17]. GBM of affected dogs showed changes similar to Alport syndrome by electron microscopy, and was found to lack the {alpha}3(IV) and {alpha}4(IV) chains [18,19]. Expression of the {alpha}5(IV) chain in the GBM is reduced, but not absent. The mutation responsible for ARAS in English cocker spaniels has not yet been identified, although efforts to sequence the COL4A3 and COL4A4 genes in normal and affected dogs are under way.

Several transgenic models of ARAS have been developed. Two of these models involve knockouts of the murine col4a3 gene [20,21]. In the third model, the proximal portions of both the col4a3 and the col4a4 gene were deleted (this is possibly because these genes are located adjacent to each other, in a 5' to 5' orientation) [22]. The GBM of homozygous ARAS mice lacks the {alpha}3(IV), {alpha}4(IV), and {alpha}5(IV) chains, and by electron microscopy shows the basket-weave transformation characteristic of human Alport syndrome [2022]. Overt proteinuria and uraemia develop within a few months of birth in murine ARAS (Table 1Go).

Autosomal dominant Alport syndrome (ADAS)

Hood and colleagues [23,24] have described an autosomal dominant nephropathy in bull terriers with GBM changes similar to those occurring in Alport syndrome. The mutation responsible for this disorder has yet to be identified. The GBM of affected dogs does not exhibit abnormal collagen IV {alpha}-chain expression, but this does not exclude a heterozygous mutation in COL4A3 or COL4A4 as the cause of the disease.

Reseach applications of animal models of Alport syndrome

Both canine and murine models of Alport syndrome are associated with advantages and disadvantages. Canine breeding programmes are expensive to maintain, and gestation periods are relatively long. An advantage of canine models is the larger size of the animal, which will facilitate development of gene transfer protocols for the treatment of Alport syndrome that are technically applicable to the human disease [25].

Murine models have the advantage of a short gestation period. The murine forms of Alport syndrome progress very rapidly (Table 1Go). On the one hand, this minimizes the time needed to determine the effect of a therapeutic intervention. On the other hand, while prolongation of survival of a few weeks might reach statistical significance in a murine model, such an effect might be difficult to confirm in human subjects. Some apparent therapeutic effects may be strain-specific, due to the influence of a predominant modifying gene allele (see Note added in proof).

Animal models of Alport syndrome will be of great value to investigators interested in the functions of the {alpha}3(IV), {alpha}4(IV), {alpha}5(IV), and {alpha}6(IV) chains. The {alpha}1(IV) and {alpha}2(IV) chains have been essential components of multi-cellular organisms for hundreds of millions of years [26]. The {alpha}3(IV)–{alpha}6(IV) chains are relatively recent additions to the mammalian protein repertoire, arising from duplication and modification of the {alpha}1(IV) and {alpha}2(IV) genes [27]. What purposes do the {alpha}3(IV)–{alpha}6(IV) chains serve? They are clearly not required for fetal survival or for the formation of kidneys, ears and eyes that are, from birth and for a substantial time thereafter, essentially normal in structure and function. The {alpha}3(IV)–{alpha}4(IV)–{alpha}5(IV) chains may protect GBM from proteolysis, since GBM composed of these chains is more resistant to proteolytic degradation than GBM containing only {alpha}1(IV)–{alpha}2(IV) chains [10]. The supramolecular assembly of {alpha}3(IV)–{alpha}4(IV)–{alpha}5(IV) protomers is stabilized by disulphide bonds not present in {alpha}1(IV)–{alpha}2(IV) networks, which may confer greater mechanical stability [8]. Adhesion of glomerular epithelial cells to GBM appears to be mediated, at least in part, by interaction between the {alpha}3ß1 integrin, the major integrin expressed by these cells, and the {alpha}3(IV) chain [28]. Podocytes may be able to adhere to an {alpha}3(IV)-deficient GBM, but maintenance of the fully differentiated podocyte phenotype may require interaction with the {alpha}3(IV) chain.

In summary, animal models of Alport syndrome offer excellent opportunities for investigation of pathogenesis and treatment of the disease, and for answering basic questions about the roles of type IV collagen chains in the biology of the kidney, cochlea, eye, and other tissues.

Note added in proof

Andrews et al. [29] have reported that quantitative trait loci influence disease progression in murine Alport syndrome. The Navasota COL4A5 mutation was presented in abstract by Melissa Cox at the Keystone Symposium ‘Genotype to Phenotype Focus on Disease’, Santa Fe, New Mexico, February 19–24, 2002.

Acknowledgments

Dr Kashtan's work is supported by the National Institutes of Health (DK57676).

Notes

Correspondence and offprint requests to: Clifford E. Kashtan MD, University of Minnesota Medical School, Department of Pediatrics, 420 Delaware Street SE, MMC 491, Minneapolis, Minnesota, 55455 USA. Email: kasht001{at}umn.edu Back

References

  1. Jais JP, Knebelmann B, Giatras I et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol2000; 11: 649–657[Abstract/Free Full Text]
  2. Heidet L, Arrondel C, Forestier L et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol2001; 12: 97–106[Abstract/Free Full Text]
  3. Boye E, Mollet G, Forestier L et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet1998; 63: 1329–1340[ISI][Medline]
  4. van der Loop FTL, Heidet L, Timmer EDJ et al. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int2000; 58: 1870–1875[ISI][Medline]
  5. Ciccarese M, Casu D, Wong FK et al. Identification of a new mutation in the {alpha}4(IV) collagen gene in a family with autosomal dominant Alport syndrome and hypercholesterolaemia. Nephrol Dial Transplant2001; 16: 2008–2012[Abstract/Free Full Text]
  6. Heath KE, Campos-Barros A, Toren A et al. Nonmuscle mysoin heavy chain IIA mutations define a spectrum of autosmal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein and Alport-like syndromes. Am J Hum Genet2001; 69: 1033–1045[ISI][Medline]
  7. Arrondel C, Vodovar N, Knebelmann B et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndrome. J Am Soc Nephrol2002; 13: 65–74[Abstract/Free Full Text]
  8. Gunwar S, Ballester F, Noelken M et al. Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J Biol Chem1998; 273: 8767–8775[Abstract/Free Full Text]
  9. Kashtan CE, Kim Y. Distribution of the {alpha}1 and {alpha}2 chains of collagen IV and of collagens V and VI in Alport syndrome. Kidney Int1992; 42: 115–126[ISI][Medline]
  10. Kalluri R, Shield CF, Todd P et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest1997; 99: 2470–2478[Abstract/Free Full Text]
  11. Harvey SJ, Zheng K, Sado Y et al. Role of distinct type IV collagen networks in glomerular development and function. Kidney Int1998; 54: 1857–1866[ISI][Medline]
  12. Kashtan CE, Kim Y, Lees GE et al. Abnormal glomerular basement membrane laminins in murine, canine, and human Alport syndrome: aberrant laminin alpha2 deposition is species independent. J Am Soc Nephrol2001; 12: 252–260[Abstract/Free Full Text]
  13. Jansen B, Thorner PS, Singh A et al. Hereditary nephritis in samoyed dogs. Am J Pathol1984; 116: 175–178[ISI][Medline]
  14. Zheng K, Thorner PS, Marrano P et al. Canine X chromosome-linked hereditary nephritis: a genetic model for human X-linked hereditary nephritis resulting from a single base mutation in the gene encoding the {alpha}5 chain of collagen type IV. Proc Natl Acad Sci USA1004; 91: 3989–3993[Abstract]
  15. Lees G, Helman RG, Kashtan CE et al. A new form of X-linked dominant hereditary nephritis in dogs. Am J Vet Res1999; 60: 373–383[ISI][Medline]
  16. Macdougall DF, Nash AS, Cattanach BM. Control scheme for familial nephropathy in cocker spaniels (letter). Vet Rec1987; 121: 134
  17. Koeman JP, Ezilius JW, Biewenga WJ et al. Zur familiaren nephropathie der cockerspaniel. Dtsch Tierarztl Wochenschr1989; 96: 174–179[ISI][Medline]
  18. Lees GE, Wilson PD, Helman RG et al. Glomerular ultrastructural changes similar to hereditary nephritis in 4 English cocker spaniel dogs. J Vet Intern Med1987; 11: 80–85
  19. Lees G, Helman RG, Kashtan CE et al. A model of autosomal recessive Alport syndrome in English cocker spaniel dogs. Kidney Int1998; 54: 706–719[ISI][Medline]
  20. Cosgrove D, Meehan DT, Grunkemeyer JA et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev1996; 10: 2981–2992[Abstract]
  21. Miner JJ, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen {alpha}3(IV): implications for Alport syndrome. J Cell Biol1996; 135: 1403–1413[Abstract]
  22. Lu W, Phillips CL, Killen PD et al. Insertional mutation of the collagen genes Col4a3 and Col4a4 in a mouse model of Alport syndrome. Genomics1999; 61: 113–124[ISI][Medline]
  23. Hood JC, Savige J, Hendtlass A et al. Bull terrier hereditary nephritis: a model for autosomal dominant Alport syndrome. Kidney Int1995; 47: 758–765[ISI][Medline]
  24. Hood JC, Savige J, Seymour AE et al. Ultrastructural appearance of renal and other basement membranes in the Bull terrier model of autosomal dominant hereditary nephritis. Am J Kidney Dis2000; 36: 378–391[ISI][Medline]
  25. Heikkila P, Tibell A, Morita T et al. Adenovirus-mediated transfer of type IV collagen alpha 5 chain cDNA into swine kidney in vivo: deposition of the protein into the glomerular basement membrane. Gene Ther2001; 8: 882–890[ISI][Medline]
  26. Czaker R. Extracellular (ECM) components in a very primitive multicellular animal, the dicyemid mesozoan Katharella antarctica. Anat Rec2000; 259: 52–59[ISI][Medline]
  27. Zhou J, Reeders ST. The {alpha} chains of type IV collagen. Contrib Nephrol1996; 117: 80–105[Medline]
  28. Krishnamurti U, Chen Y, Michael A et al. Integrin-mediated interactions between primary T-SV40 immortalized human glomerular epithelial cells and type IV collagen. Lab Invest1996; 74: 650–657[ISI][Medline]
  29. Andrews KL, Mudd JL, Cong L, Miner JH. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol2002; 160: 721–730[Abstract/Free Full Text]